One to Watch: DenovoSkin Shows Promise in Reconstructive Surgery, Burns
The Dermatology Digest
JULY 14, 2024
CUTISS AG’s denovoSkin performed well in a Phase 2 clinical trial of patients undergoing reconstructive skin surgery for various conditions, according to an interim analysis of the data. Following the announced positive primary endpoint in Q1 2023, the one-year readout evaluated long term safety and scar quality. Stay tuned.
Let's personalize your content